医学
放射性配体
前列腺癌
谷氨酸羧肽酶Ⅱ
前列腺
肿瘤科
癌症
前列腺癌的治疗
内科学
受体
作者
Ludmila Santiago Almeida,Elba Etchebehere,Irene García Megías,Adriana K. Calapaquí Terán,Boris Hadaschik,Patrick M. Colletti,Ken Herrmann,Francesco Giammarile,Roberto C. Delgado Bolton
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2023-10-25
卷期号:49 (1): 45-55
被引量:4
标识
DOI:10.1097/rlu.0000000000004919
摘要
Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI